Sign in
Taking peoplePhase 1/2

Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control

Key facts

Who runs it
Ruihua Wei
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
410 people, planned
Started
1 Feb 2024
Planned end
31 Mar 2026
Type of study
Interventional, 5 groups
Treatments tested
  • DIMS
  • The 0.02% ATP Group
  • The 0.04% ATP Group
  • 0.02%ATP+DIMS
  • 0.04%ATP+DIMS
Record updated
8 September 2025

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • School-age children aged 6 to 12 years (including boundary value)
  • Children with moderate or high myopia (subjective refraction after cycloplegia: -9.00D≤spherical equivalent (SE)≤-3.00D, with-rule astigmatism (C)≤2.00D, against-rule astigmatism (C)≤1.00D, anisometropia of both eyes≤2.50D)
  • Binocular best corrected visual acuity (BCVA)≥0.8 (five-point visual acuity 4.9)
  • Agree with the study scheme and sign the informed consent
  • Note: if both eyes meet the inclusion criteria, the eye with higher spherical equivalent is the study eye; if one eye meets the inclusion criteria, the eye is the study eye

Who cannot take part

  • Used or currently using orthokeratology, multifocal contact lenses, defocusing framework lenses, atropine eye drops and other myopia control means in the past month; used red light treatment in the past
  • Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
  • With congenital eye disease, such as congenital cataract, congenital retinal disease
  • Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
  • Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
  • Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
  • Children with obvious strabismus and amblyopia
  • Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP \>21mmHg or binocular IOP difference ≥5mmHg)
  • Optic nerve damage or congenital optic nerve dysfunction
  • Can not be regularly checked
  • The adjustment range is less than 8D or obvious near difficulties
  • Other reasons researchers think it is not suitable for inclusion in researchers

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 6 and 12 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.

The 5 groups in the trial

  • The DIMS GroupTreatment being tested

    wear DIMS ,and use placebo,once nightly, both eye

    Treatment: DIMS

  • 0.02% ATPTreatment being tested

    wear SP, and use 0.02%ATP eye drops, once nightly, both eye

    Treatment: The 0.02% ATP Group

  • 0.04%ATPTreatment being tested

    wear SP, and use 0.04%ATP eye drops, once nightly, both eye

    Treatment: The 0.04% ATP Group

  • 0.02%ATP+DIMSTreatment being tested

    wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye

  • 0.04%ATP+DIMSTreatment being tested

    wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Low-concentration Atropine Eye Drops (0.02%, 0.04%) Combined With Defocus Incorporated Multiple Segments (DIMS) for Moderate and High Myopia Control
Criteria questions
Built from NCT06523504, who can take part
Record updated
8 September 2025